[HTML] springer.comFull View

[HTML][HTML] The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

E Vercalsteren, D Karampatsi, C Buizza… - Cardiovascular …, 2024 - Springer
Abstract Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …
相关文章

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

E Vercalsteren, D Karampatsi, C Buizza, T Nyström… - 2023 - researchsquare.com
Abstract Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …
[HTML] nih.gov

[HTML][HTML] The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

E Vercalsteren, D Karampatsi, C Buizza… - Cardiovascular …, 2024 - ncbi.nlm.nih.gov
Abstract Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

E Vercalsteren, D Karampatsi… - Cardiovascular …, 2024 - pubmed.ncbi.nlm.nih.gov
Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

E Vercalsteren, D Karampatsi, C Buizza… - Cardiovascular …, 2024 - lup.lub.lu.se
Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.

E Vercalsteren, D Karampatsi, C Buizza… - Cardiovascular …, 2024 - europepmc.org
Abstract Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …
[HTML] biomedcentral.com

[HTML][HTML] The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

E Vercalsteren, D Karampatsi… - Cardiovascular …, 2024 - cardiab.biomedcentral.com
Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

E Vercalsteren, D Karampatsi, C Buizza… - Cardiovascular …, 2024 - portal.research.lu.se
Abstract Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.

E Vercalsteren, D Karampatsi… - Cardiovascular …, 2024 - search.ebscohost.com
Abstract Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.

E Vercalsteren, D Karampatsi, C Buizza… - Cardiovascular …, 2024 - europepmc.org
Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …